Corvus Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRVS and other ETFs, options, and stocks.

About CRVS

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor.

CEO

Richard A. Miller

CEORichard A. Miller

Employees

Employees31

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

2014

Founded2014

Employees

Employees31

CRVS Key Statistics

Market cap

415.79M

Market cap415.79M

Price-Earnings ratio

-5.21

Price-Earnings ratio-5.21

Dividend yield

—

Dividend yield—

Average volume

523.36K

Average volume523.36K

High today

$5.59

High today$5.59

Low today

$5.22

Low today$5.22

Open price

$5.32

Open price$5.32

Volume

414.16K

Volume414.16K

52 Week high

$10.00

52 Week high$10.00

52 Week low

$2.54

52 Week low$2.54

CRVS News

Simply Wall St 3d

Is Corvus Pharmaceuticals, Inc. Trading At A 49% Discount?

Advertisement Key Insights Corvus Pharmaceuticals' estimated fair value is US$10.34 based on 2 Stage Free Cash Flow to Equity Current share price of US$5.32...

Analyst ratings

100%

of 6 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own CRVS. This list is generated using Robinhood data, and it’s not a recommendation.